Nacer E. Dean Abrouk. Prior to joining DURECT, Dr. Abrouk was the Director of Statistics for ALZA Corporation, a Johnson & Johnson subsidiary, where he was responsible since January 2006 for overall statistical aspects of product development for worldwide regulatory submissions spanning several therapeutic areas, including pain management, oncology and urology. His most recent regulatory submissions include Dapoxetene, OROS Hydromorphone and IONSYS Fentanyl. From 2001 to 2005, Dr. Abrouk held various positions at Amgen Inc., most recently as a Senior Manager in Nephrology and Oncology, where he was responsible for the design and analysis of Phase 3 and 4 clinical studies. In addition, from 1992 to 2001, Dr. Abrouk held various positions at public and private companies, providing consultative services on statistical data analysis, data management, and report writing. Clients included Eli Lilly, Parke-Davis, Biomet Inc. and the Terre Haute Medical Laboratory. Dr. Abrouk received his undergraduate degree in Mathematics and Computer Science Microbiology from Constantine University, and his M.S. and Ph.D. in Statistics from Michigan State University.